Diagnostic Imaging Agents for Alzheimer’s Disease: Copper Radiopharmaceuticals that Target Aβ Plaques
Citations Over TimeTop 10% of 2013 papers
Abstract
One of the pathological hallmarks of Alzheimer's disease is the presence of amyloid-β plaques in the brain and the major constituent of these plaques is aggregated amyloid-β peptide. New thiosemicarbazone-pyridylhydrazine based ligands that incorporate functional groups designed to bind amyloid-β plaques have been synthesized. The new ligands form stable four coordinate complexes with a positron-emitting radioactive isotope of copper, (64)Cu. Two of the new Cu(II) complexes include a functionalized styrylpyridine group and these complexes bind to amyloid-β plaques in samples of post-mortem human brain tissue. Strategies to increase brain uptake by functional group manipulation have led to a (64)Cu complex that effectively crosses the blood-brain barrier in wild-type mice. The new complexes described in this manuscript provide insight into strategies to deliver metal complexes to amyloid-β plaques.
Related Papers
- → Pathological Gambling and Substance Misuse: A Review of the Literature(1998)80 cited
- Analysis of the relationship between C-reactive protein and the pathological changes of coronary atherosclerosis(2005)
- Study on pathological diagnosis of pathological changes of 457 patients with atypical squamous cells(2008)
- The Clinic Means of Ultrasonic for Physical Gallbladder Bulging Pathological Changes(2004)
- Review of clinical and pathological characteristics in 68 children with henoch-schsnlein purpura nephritics(2009)